Product review on the JE vaccine IXIARO

Human Vaccines and Immunotherapeutics

Volumn 11, Issue 2, 2015, Pages 411-420

  Firbas, Christa ^a   Jilma, Bernd ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Inactivated vaccine; Japanese encephalitis virus

Indexed keywords

JAPANESE ENCEPHALITIS VACCINE; NEUTRALIZING ANTIBODY; ALUMINUM POTASSIUM SULFATE; ALUMINUM SULFATE; IMMUNOLOGICAL ADJUVANT; INACTIVATED VACCINE;

ANTIBODY TITER; DRUG TOLERABILITY; FOOD AND DRUG ADMINISTRATION; GENOTYPE; HUMAN; IMMUNE RESPONSE; JAPANESE ENCEPHALITIS VIRUS; MASS IMMUNIZATION; NONHUMAN; PATIENT SAFETY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PUBLIC HEALTH; REVIEW; SEROCONVERSION; VIRUS ENCEPHALITIS; ADVERSE DRUG REACTION; CLINICAL TRIAL (TOPIC); DRUG APPROVAL; ENCEPHALITIS, JAPANESE; IMMUNOLOGY; ISOLATION AND PURIFICATION;

ADJUVANTS, IMMUNOLOGIC; ALUM COMPOUNDS; CLINICAL TRIALS AS TOPIC; DRUG APPROVAL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; ENCEPHALITIS VIRUS, JAPANESE; ENCEPHALITIS, JAPANESE; HUMANS; JAPANESE ENCEPHALITIS VACCINES; VACCINES, INACTIVATED;

EID: 84964693735     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/21645515.2014.983412     Document Type: Review

References (76)

1. Kuno G, Chang GJ, Tsuchiya KR, Karabatsos N, Cropp CB. Phylogeny of the genus Flavivirus. J Virol 1998; 72:73-83; PMID:9420202.
2. Mackenzie JS, Barrett AD, Deubel V. The Japanese encephalitis serological group of flaviviruses: a brief introduction to the group. Curr Top Microbiol Immunol 2002; 267:1-10; PMID:12082984.
3. Solomon T, Ni H, Beasley DW, Ekkelenkamp M, Cardosa MJ, Barrett AD. Origin and evolution of Japanese encephalitis virus in southeast Asia. J Virol 2003; 77:3091-8; PMID:12584335; http://dx.doi.org/10.1128/JVI.77.5.3091-3098.2003.
4. Mackenzie JS, Gubler DJ, Petersen LR. Emerging flaviviruses: the spread and resurgence of Japanese encephalitis, West Nile and dengue virus. Nat Med 2004; 10: S98-109; PMID:15577938; http://dx.doi.org/10.1038/nm1144.
5. Vaughn DW, Hoke CH. The epidemiology of Japanese encephalitis: prospects for prevention. Epidem Rev 1992; 14:197-221; PMID:1337744.
6. Solomon T. Control of Japanese encephalitis—within our grasp? N Engl J Med 2006; 355:869-71; PMID:16943399; http://dx.doi.org/10.1056/NEJMp058263.
7. Solomon T, Whitley RJ. Arthropod-borne viral encephalitides. In: Scheld M, Whitley RJ, Marra C, eds. Infections of the central nervous system, 2nd edn. Philidelphia, PA: Lippincott Williams and Wilkins, 2004.
8. Campbell GL, Hills SL, Fischer M, Jacobson JA, Hoke CH, Hombach JM, Marfin AA, Solomon T, Tsai TF, Tsu VD, et al. Estimated global incidence of Japanese encephalitis: a systematic review. Bull World Health Organ 2011; 89(10):766-74; PMID:22084515; http://dx.doi.org/10.2471/BLT.10.085233.
9. Igarashi A. Epidemiology and control of Japanese encephalitis. Wld Hlth Stats Quart 1992; 45:299-305.
10. Keiser J, Maltese MF, Erlanger TE, Bos R, Tanner M, Singer BH, Utzinger J. Effect of irrigated rice agriculture on Japanese encephalitis, including challenges and opportunities for integrated vector management. Acta Trop 2005; 95:40-57; PMID:15878762; http://dx.doi.org/10.1016/j.actatropica.2005.04.012.
11. Umenai T, Krzysko R, Bektimirov TA, Assaad FA. Japanese encephalitis: current worldwide status. Bull World Health Organ 1985; 63:625-31; PMID:3002650.
12. Hanna JN, Ritchie SA, Phillips DA, Shield J, Bailey MC, Mackenzie JS, Poidinger M, McCall BJ, Mills PJ. An outbreak of Japanese encephalitis in the Torres Strait, Australia, 1995. Med J Aust 1996; 165:256-60; PMID:8816682.
13. Fischer M, Lindsey N, Staples JE, Hills S; Centers for Disease Control and Prevention (CDC). Japanese encephalitis vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2010; 59(RR-1):1-27.
14. Scherer WF, Kitaoka M, Okuno T, Ogata T. Ecologic studies of Japanese encephalitis virus in Japan. VII. Human infection. Am J Trop Med Hyg 1959; 8:707-15; PMID:14442655.
15. Shlim DR, Solomon T. Japanese encephalitis vaccine for travelers: exploring the limits of risk. Clin Infect Dis 2002; 352:183-8; PMID:12087525; http://dx.doi. org/10.1086/341247.
16. Kumar R, Mathur A, Kumar A, Sharma S, Chakraborty S, Chaturvedi UC: Clinical features & prognostic indicators of Japanese encephalitis in children in Lucknow (India). Indian J Med Res 1990; 91:321-7; PMID:2176644.
17. Solomon T, Vaughn DW. Pathogenesis and clinical features of Japanese encephalitis and West Nile virus infections. Curr Top Microbiol Immunol 2002;267:171-94; PMID:12082989.
18. Burke DS, Leake CJ. Japanese encephalitis. In: Monath TP, editor. The arboviruses: epidemiology and ecology. Boca Raton: CRC Press; 1988. p. 63-92.
19. Tsai T. Japanese encephalitis vaccines. WB Saunders. 1999. pp. 671-713.
20. Parida M, Dash PK, Tripathi NK, Ambuj Sannarangaiah S, Saxena P, Agarwal S, Sahni AK, Singh SP, Rathi AK, et al. Japanese encephalitis outbreak, India, 2005. Emerg Infect Dis 2006; 12:1427-30; PMID:17073095; http://dx.doi.org/10.3201/eid1209.060200.
21. Mathur A, Arora KL, Chaturvedi UC. Host defence mechanisms against Japanese encephalitis virus infection in mice. J Gen Virol. 1983 Apr;64 (Pt 4):805-11; PMID:6300303.
22. AG Aleyas, JA George, YW Han, MM Rahman, SJ Kim, SB Han, BS Kim, K, Kim, SK Eo Functional modulation of dendritic cells and macrophages by Japanese encephalitis virus through MyD88 adaptor molecule-dependent and-independent pathways J. Immunol (2009); 183 (4) pp. 2462-74; PMID:19635909; http://dx.doi.org/10.4049/jimmunol.0801952.
23. Mason PW, Pincus S, Fournier MJ, Mason TL, Shope RE, Paoletti E. Japanese encephalitis virus-vaccinia recombinants produce particulate forms of the structural membrane proteins and induce high levels of protection against lethal JEV infection. Virology 1991; 180(1):294-305; PMID:1845826; http://dx.doi.org/10.1016/0042-6822(91)90034-9.
24. Hombach J, Solomon T, Kurane I, Jacobson J, Wood D. Report on a WHO consultation on immunological endpoints for evaluation of new Japanese encephalitis vaccines, WHO, Geneva, 2-3 September, 2004. Vaccine 2005;23:5205-11; PMID:16055233; http://dx.doi.org/10.1016/j.vaccine.2005.07.002.
25. Hennessy S, Strom BL, Bilker WB, et al. Effectiveness of live-attenuated Japanese encephalitis vaccine (SA14-14-2): a case-control study. Lancet 1996; 347:1583-86; PMID:8667866; http://dx.doi.org/10.1016/S0140-6736(96)91075-2.
26. Bista MB, Banerjee MK, Shin SH, Tandan JB, Kim MH, Sohn YM, Ohrr HC, Tang JL, Halstead SB. Efficacy of single-dose SA14-14-2 vaccine against Japanese encephalitis: a case control study. Lancet 2001; 358:791-95; PMID:11564484; http://dx.doi.org/10.1016/S0140-6736(01)05967-0.
27. Ohrr H, Tandan JB, Sohn YM, Shin SH, Pradhan DP, Halstead SB. Effect of single dose of SA14-14-2 vaccine 1 year after immunisation in Nepalese children with Japanese encephalitis: a case-control study. Lancet 2005; 366:1375-78; PMID:16226615; http://dx.doi. org/10.1016/S0140-6736(05)67567-8.
28. Tsai TF. New initiatives for the control of Japanese encephalitis by vaccination: minutes of a WHO/CVI meeting, Bangkok, Thailand, 13–15 October 1998. Vaccine 2000; 18 (suppl 2): 1-25; PMID:10821969; http://dx.doi.org/10.1016/S0264-410X(00)00037-2.
29. Daly J, Solomon T. Japanese encephalitis virus. In: The Immunological Basis for Immunization Series (Module 13). WHO Press, Geneva, Switzerland (2010).
30. Seligman SJ, Gould EA. Live flavivirus vaccines: reasons for caution. Lancet 2004; 363: 2073-75; PMID:15207960; http://dx.doi.org/10.1016/S0140-6736(04)16459-3.
31. Hombach J, Kurane I,Wood D. Arguments for live flavivirus vaccines. Lancet 2004; 364: 498-99; PMID:15302184; http://dx.doi.org/10.1016/S0140-6736(04)16800-1.
32. Hoke CH, Nisalak A, Sangawhipa N, Jatanasen S, Laorakapongse T, Innis BL, Kotchasenee S, Gingrich JB, Latendresse J, Fukai K. Protection against Japanese encephalitis by inactivated vaccines. N Engl J Med 1988; 319: 608-14; PMID:2842677; http://dx.doi. org/10.1056/NEJM198809083191004.
33. Marfin AA, Gubler DJ. Japanese encephalitis: the need for a more effective vaccine. Lancet. 2005; 366 (9494):1335-7; PMID:16226596; http://dx.doi.org/10.1016/S0140-6736(05)67543-5.
34. Ostlund MR, Kan B, Karlsson M, Vene S. Japanese encephalitis in a swedish tourist after travelling to Java and Bali. Scand J Infect Dis 2004; 36: 512-13; PMID:15307587; http://dx.doi.org/10.1080/00365540410020640.
35. WHO. Wkly Epidemiol Record 2005; 80: 241-48. http://www.who.int/wer/2005/wer8028.pdf (accessed Sept 12, 2007)
36. Tauber E, Kollaritsch H, Korinek M, Rendi-Wagner P, Jilma B, Firbas C, Schranz S, Jong E, Klingler A, Dewasthaly S, et al. Safety and immunogenicity of a Verocell-derived, inactivated Japanese encephalitis vaccine: a non-inferiority, phase III, randomised controlled trial. Lancet. 2007; 370(9602):1847-53; PMID:18061060; http://dx.doi.org/10.1016/S0140-6736(07)61780-2.
37. Kuzuhara S, Nakamura H, Hayashida K, Obata J, Abe M, Sonoda K, Nishiyama K, Sugawara K, Takeda K, Honda T, et al. Non-clinical and phase I clinical trials of a Vero cell-derived inactivated Japanese encephalitis vaccine. Vaccine 2003; 21(31):4519-26; PMID:14575762; http://dx.doi.org/10.1016/S0264-410X(03)00506-1.
38. Dubischar-Kastner K, Kanesa-Thasan N: Vaccinating against Japanese encephalitis virus: what have we learned from recent clinical trials? Expert Rev. Vaccines (2012); 11(10), 1159-61; PMID:23176646.
39. Eckels KH, Yu XY, Dubois DR, Marchette NJ, Trent DW, Johnson AJ. Japanese encephalitis virus live attenuated vaccine, Chinese strain SA14-14-2: adaptation to primary canine kidney cell cultures and preparation of a vaccine for human use. Vaccine 1988;6:513-8; PMID:3149829; http://dx.doi.org/10.1016/0264-410X(88)90103-X
40. Montagnon BJ, Vincent-Falquet JC. Experience with theVero Cell line. Dev Biol Stand 1998;93:119-23; PMID:9737386.
41. Srivastava AK, Putnak JR, Lee SH, Hong SP, Moon SB, Barvir DA, Zhao B, Olson RA, Kim SO, Yoo WD, et al. Eckels KHA purified inactivated Japanese encephalitis virus vaccine made in Vero cells. Vaccine 2001; 19 (31):4557-65; PMID:11483284; http://dx.doi.org/10.1016/S0264-410X(01)00208-0.
42. Plotkin SA. Correlates of protection induced by vaccination. Clin Vaccine Immunol 2010; 17(7):1055-65; PMID:20463105; http://dx.doi.org/10.1128/CVI.00131-10.
43. ®)) induced neutralizing antibody titers. Vaccine 2011; 29(35):5925-31; PMID:21723353; http://dx.doi.org/10.1016/j. vaccine.2011.06.062.
44. Lyons A, Kanesa-thasan N, Kuschner RA, Eckels KH, Putnak R, Sun W, Burge R, Towle AC, Wilson P, Tauber E, et al. A Phase 2 study of a purified, inactivated virus vaccine to prevent Japanese encephalitis. Vaccine 2007; 25(17):3445-53; PMID:17241714; http://dx.doi.org/10.1016/j.vaccine.2006.12.046.
45. Kaltenböck A, Dubischar-Kastner K, Schuller E, Datla M, Klade CS, Kishore TS. Immunogenicity and safety of IXIARO (IC51) in a Phase II study in healthy Indian children between 1 and 3 years of age. Vaccine 2010; 28(3):834-9; PMID:19857447; http://dx.doi.org/10.1016/j.vaccine.2009.10.024.
46. Tauber E, Kollaritsch H, von Sonnenburg F, Lademann M, Jilma B, Firbas C, Jelinek T, Beckett C, Knobloch J, McBride WJ, et al. Randomized, doubleblind, placebo-controlled phase 3 trial of the safety and tolerability of IC51, an inactivated Japanese encephalitis vaccine. J Infect Dis 2008; 198(4):493-9; PMID:18588481; http://dx.doi.org/10.1086/590116.
47. Schuller E, Jilma B, Voicu V, Golor G, Kollaritsch H, Kaltenböck A, Klade C, Tauber E. Long-term immunogenicity of the new Vero cell-derived, inactivated Japanese encephalitis virus vaccine IC51 Six and 12 month results of a multicenter follow-up phase 3 study. Vaccine 2008; 26(34):4382-6; PMID:18599165; http://dx.doi.org/10.1016/j.vaccine.2008.05.081.
48. Dubischar-Kastner K, Eder S, Jilma B, Golor G, Hatzenbichler E, Kollaritsch H, Müller Z, Voicu V, Westritschnig K. Persistence of Antibodies 60 months after Vaccination with the Inactivated Japanese Encephalitis Vaccine IXIARO®, IC51. Presented at the 60th ASTMH ASTMH Annual Meeting, Philadelphia, USA, December 4-8, 2011, abstract no LB-2357.
49. Schuller E, Klade CS, Wölfl G, Kaltenböck A, Dewasthaly S, Tauber E. Comparison of a single, high-dose vaccination regimen to the standard regimen for the investigational Japanese encephalitis vaccine, IC51: a randomized, observer-blind, controlled Phase 3 study. Vaccine 2009; 27(15):2188-93; PMID:19200452; http://dx.doi.org/10.1016/j.vaccine.2008.12.062.
50. Dubischar-Kastner K, Eder S, Buerger V, Gartner-Woelfl G, Kaltenboeck A, Schuller E, Tauber E, Klade C. Long-term immunity and immune response to a booster dose following vaccination with the inactivated Japanese encephalitis vaccine IXIARO, IC51. Vaccine 2010; 28(32):5197-202; PMID:20541581; http://dx. doi.org/10.1016/j.vaccine.2010.05.069.
51. ®, IC51. Vaccine 2011; 29(14):2607-12; PMID:21288804; http://dx.doi.org/10.1016/j.vaccine.2011.01.058.
52. Kaltenböck A, Dubischar-Kastner K, Eder G, Jilg W, Klade C, Kollaritsch H, Paulke-Korinek M, von Sonnenburg F, Spruth M, Tauber E, et al. Safety and immunogenicity of concomitant vaccination with the cell-culture based Japanese Encephalitis vaccine IC51 and the hepatitis A vaccine HAVRIX1440 in healthy subjects: A singleblind, randomized, controlled Phase 3 study. Vaccine 2009; 27(33):4483-9; PMID:19486955; http://dx.doi. org/10.1016/j.vaccine.2009.05.034.
53. Dubischar-Kastner K, Kaltenboeck A, Klingler A, Jilma B, Schuller E. Safety analysis of a Vero-cell culture derived Japanese encephalitis vaccine, IXIARO (IC51), in 6 months of follow-up. Vaccine 2010; 28(39):6463-9; PMID:20673824; http://dx.doi.org/10.1016/j. vaccine.2010.07.040.
54. Centers for Disease Control and Prevention (CDC). Recommendations for use of a booster dose of inactivated vero cell culture-derived Japanese encephalitis vaccine: advisory committee on immunization practices, 2011. MMWR Morb Mortal Wkly Rep 2011; 60 (20):661-3; PMID:21617632.
55. Hills SL, Griggs AC, Fischer M. Japanese encephalitis in travelers from non-endemic countries, 1973-2008. Am J Trop Med Hyg 2010; 82(5):930-6; PMID:20439978; http://dx.doi.org/10.4269/ajtmh.2010.09-0676.
56. Jelinek T, Burchard GD, Dieckmann S, Bühler S, Kollaritsch H, Nothdurft HD, Reisinger E, Costantini M, Gniel D, Bosse D et al. Immunogenicity and safety of an accelerated dosing regimen of Japanese Encephalitis inactivated absorbed vaccine for travelers: A phase III randomized study in healthy adults. Presented at the 5th Northern European Conference on Travel Medicine June 5th –8th 2014 Bergen, Norway, Abstract P2.9.
57. Jelinek T. IXIARO updated: overview of clinical trials and developments with the inactivated vaccine against Japanese encephalitis. Expert Rev Vaccines 2013; 12 (8):859-69; PMID:23984958; http://dx.doi.org/10.1586/14760584.2013.835638.
58. Alberer M, Burchard G, Jelinek T, Reisinger E, Beran J, Meyer S, Forleo-Neto E, Gniel D, Dagnew AF, Arora AK. Co-administration of a meningococcal glycoconjugate ACWY vaccine with travel vaccines: a randomized, open-label, multi-center study. Travel Med Infect Dis 2014 Sep-Oct; 12(5):485–93.
59. Schuller E, Klade CS, Heinz FX, Kollaritsch H, Rendi-Wagner P, Jilma B, Tauber E. Effect of pre-existing anti-tick-borne encephalitis virus immunity on neutralising antibody response to the Vero cell-derived, inactivated Japanese encephalitis virus vaccine candidate IC51. Vaccine 2008 Nov 11;26(48):6151-6; PMID:18804132; http://dx.doi.org/10.1016/j. vaccine.2008.08.056.
60. Campbell GL, Hills SL, Fischer M, Jacobson JA, Hoke CH, Hombach JM, Marfin AA, Solomon T, Tsai TF, Tsu VD, et al. Estimated global incidence of Japanese encephalitis: a systematic review. Bull World Health Organ 2011; 89(10):766-74, 774A-774E; PMID: 22084515; http://dx.doi.org/10.2471/BLT.10.085233.
61. ®). Vaccine 2011; 29(47):8669-76; PMID:21907747; http://dx.doi.org/10.1016/j.vaccine.2011.08.117.
62. Rüggeberg JU, Gold MS, Bayas JM, Blum MD, Bonhoeffer J, Friedlander S, de Souza Brito G, Heininger U, Imoukhuede B, Khamesipour A, et al; Brighton Collaboration Anaphylaxis Working Group. Anaphylaxis: case definition and guidelines for data collection, analysis, and presentation of immunization safety data. Vaccine 2007; 25(31):5675-84; PMID:17448577; http://dx.doi.org/10.1016/j.vaccine.2007.02.064.
63. ®-Experience Three Years after Launch. Presented at the 13th Conference of the International Society of Travel Medicine, Maastricht, The Netherlands, 19 –23 May 2013. PO14.05.
64. Lloyd JC, Haber P, Mootrey GT, Braun MM, Rhodes PH, Chen RT; VAERS Working Group. Adverse event reporting rates following tetanus-diphtheria and tetanus toxoid vaccinations: data from the Vaccine Adverse Event Reporting System (VAERS), 1991-1997. Vaccine 2003; 21(25-26):3746-50; PMID:12922107; http://dx.doi.org/10.1016/S0264-410X(03)00404-3.
65. Rosenthal S, Chen R. The reporting sensitivities of two passive surveillance systems for vaccine adverse events. Am J Public Health 1995;85:1706-9; PMID:7503351; http://dx.doi.org/10.2105/AJPH.85.12.1706.
66. ®)V) in children. Vaccine 2012; 30(41):5967-72. Epub 2012 Jul 25; PMID:22841478; http://dx.doi.org/10.1016/j. vaccine.2012.07.034.
67. Yokoye H. Newly development of Vero cell-derived Japanese Encephalitis vaccine JEIMMUGEN (The Chemo-Sero-Therapeutic Research Institute, KAKETSUKEN). Presented at: 4th Annual World Vaccine Congress Asia 2010 Singapore, 10 June 2010.
68. Hasegawa H, Yoshida M, Kobayashi Y, Fujita S. Antigenic analysis of Japanese encephalitis viruses in Asia by using monoclonal antibodies. Vaccine 1995; 13 (17):1713-21; PMID:8719524; http://dx.doi.org/10.1016/0264-410X(95)00099-M
69. Fulmali PV, Sapkal GN, Athawale S, Gore MM, Mishra AC, Bondre VP. Introduction of Japanese encephalitis virus genotype I, India. Emerg Infect Dis 2011 Feb;17(2):319-21; PMID:21291622; http://dx.doi.org/10.3201/eid1702.100815.
70. Erra EO, Askling HH, Yoksan S, Rombo L, Riutta J, Vene S, Lindquist L, Vapalahti O, Kantele A. Crossprotection elicited by primary and booster vaccinations against Japanese encephalitis: a two-year follow-up study. Vaccine 2013; 32(1):119-23; PMID:24176496; http://dx.doi.org/10.1016/j.vaccine.2013.10.055.
71. Woolpert T, Staples JE, Faix DJ, Nett RJ, Kosoy OI, Biggerstaff BJ, Johnson BW, Sracic M, Fischer M. Immunogenicity of one dose of Vero cell culturederived Japanese encephalitis (JE) vaccine in adults previously vaccinated with mouse brain-derived JE vaccine. Vaccine 2012 Apr 26;30(20):3090-6; PMID:22406277; http://dx.doi.org/10.1016/j.vaccine.2012.02.063.
72. Dubischar-Kastner K, Kanesa-Thasan N. Vaccinating against Japanese encephalitis virus: what have we learned from recent clinical trials? Expert Rev Vaccines. 2012 Oct;11(10):1159-61; PMID:23176646.
73. ®, IC51, in Filipino children aged 2 months to < 18 years. Presented at: 9th Asia Pacific Travel Health Conference, Singapore, 2-5 May 2012.
74. Dubischar-Kastner K. 24-Months Antibody Persistence in Children With and Without a Booster Dose of an Inactivated Japanese Encephalitis Vaccine, JE-VC, IC51. Abstract P2.8 Presented at the 5th NECTM, June 5th-8th, 2014.
75. Dubischar-Kastner K. Safety and Immunogenicity Data for Inactivated Japanese Encephalitis Vaccine (JEVC), IC51, in Children from JE non-endemic countries Abstract P 2.7 Presented at the 5th NECTM, June 5th-8th, 2014.
76. Centers for Disease Control and Prevention (CDC). Use of Japanese encephalitis vaccine in children: recommendations of the advisory committee on immunization practices, 2013. MMWR Morb Mortal Wkly Rep. 2013; 62(45):898-900; PMID:24226626